← All medications

Systemic corticosteroids (prednisone representative)

Systemic glucocorticoid receptor agonist class · also known as oral corticosteroids, prednisone, prednisolone, methylprednisolone, dexamethasone

Step-7 class in a 2025 practical MCAS approach, supported by uncontrolled idiopathic-anaphylaxis records rather than an MCAS comparison.

How it relates to mast cells: Related inflammatory condition
Types of studies cited: Case series , Cohort study
Approved in the US for: severe or incapacitating allergic conditions intractable to conventional treatment (prednisone tablets)
Also covers: Prednisone, Prednisolone, Methylprednisolone, Dexamethasone

What this relationship means: Studied in people with a condition in which mast cells can contribute, but the study did not measure an effect on mast cells. This is a clinical bridge for inclusion, not a direct observation of mast cells and not an MCAS outcome. A 2025 practical-management review places this at step 7 of the sequence it describes — described for frequent episodes, with use limited by adverse effects. That is what the review reports, not a recommendation from this site.

Mechanism of action

Systemic corticosteroids bind intracellular glucocorticoid receptors and alter transcription across many immune and metabolic pathways. That broad, delayed immunomodulation differs from blocking one released mediator and from the rapid adrenergic physiology of epinephrine. Prednisone supplies the representative label on this class page; other systemic corticosteroids are not assumed to have identical formulations or regulatory language.

The 2025 practical MCAS review places oral corticosteroids at step 7 for selected severe, recurrent episodes after preceding options. Its clinical bridge is a 1996 idiopathic-anaphylaxis series in which prednisone was part of a bundled regimen, not a controlled MCAS comparison. A more recent anaphylaxis registry also recorded corticosteroid exposure, but treatment selection and event severity were not randomized.

The numbered placement reports what that practical review describes. It does not make systemic corticosteroids routine, acute first-line anaphylaxis treatment, or a substitute for the separate emergency epinephrine entry. The class-wide adverse-effect burden and the inability of the available records to isolate prednisone are central to interpreting why this entry sits late in the sequence.

Sources

Diagnosis and management of mast cell activation syndrome (MCAS) in Canada: a practical approach Peer-reviewed study 2025 PMID 41272881 · link checked 24 Aug 2026
Idiopathic anaphylaxis: a series of 335 cases Peer-reviewed study 1996 PMID 8885805 · link checked 24 Aug 2026
Managing anaphylaxis: Epinephrine, antihistamines, and corticosteroids: More than 10 years of Cross-Canada Anaphylaxis REgistry data Peer-reviewed study 2023 PMID 37689113 · link checked 24 Aug 2026
Prednisone tablets current US prescribing information Drug label · link checked 24 Aug 2026

What this evidence cannot establish

The clinical bridge is idiopathic anaphylaxis rather than a prospectively defined MCAS population. The 1996 series was uncontrolled, bundled prednisone with hydroxyzine and albuterol, reported only 132 of 335 patients as available for follow-up, and cannot isolate prednisone. A later emergency-department registry recorded prehospital corticosteroid exposure in a small minority of predominantly pediatric anaphylaxis events; the higher rates of intravenous-fluid use and admission among exposed events may reflect confounding by severity and do not establish benefit or harm. The 2025 practical sequence is guidance extrapolated from those records and expert practice, not a controlled MCAS outcome. Prednisone is only the regulatory representative for a heterogeneous class whose agents, formulations, routes, and durations differ. Current systemic-corticosteroid labeling makes immunosuppression and infection, adrenal suppression and withdrawal, metabolic and cardiovascular effects, psychiatric reactions, eye and bone effects, gastrointestinal injury, myopathy, growth effects, and interactions central boundaries.

What this page does not say

No dosing, and no claim that this works. The entry describes a published mechanism, the cited study types, and what those studies cannot establish — nothing further. Why the site is built this way.

Recently verified. Verified 24 Aug 2026